Mu-Ran Li

Mu-Ran Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YLYandi Liu
Yandi Liu
MLMu-Ran Li
Mu-Ran Li
SZShiwu Zhang
Shiwu Zhang
YLYandi Liu
Yandi Liu
Background. Gastric cancer (GC) is one of the most prevalent cancers globally. This study was designed to evaluate the potential performance of plasma SEPT9 methylation (mSEPT9) as a noninvasive biomarker for the diagnosis of GC. Methods. A total of 182 participants, i.e., 60 patients with GC, 39 with chronic superficial gastritis (CSG), 27 with chronic atrophic gastritis (CAG), 30 with gastric ulcer (GU), and 26 with gastric polys (GP), were recruited. The mSEPT9 level was measured using real-time polymerase chain reaction. Results. As a diagnostic target, mSEPT9 (1/3 algorithm) had a sensitivity of 48.33 (95% confidence interval (CI): 35.40–61.48%) and a specificity of 86.89% (95% CI: 79.28–92.09%), and mSEPT9 (2/3 algorithm) had a sensitivity of 33.33 (95% CI: 22.02–46.79%) and a specificity of 98.36% (95% CI: 93.61–99.72%). The area under the receiver operating characteristic curve (ROC) curve of mSEPT9 was 0.698 (95% CI: 0.609–0.787) for the differentiation of GC from benign gastric diseases. The effectiveness of mSEPT9 (1/3 algorithm) was superior to that of CEA, CA19-9, and CA72-4. mSEPT9 was positively correlated with T, N, M, and the clinical stage of GC. Conclusions. Plasma mSEPT9 might serve as a useful and noninvasive biomarker for the diagnosis of GC.

5 October 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LZLuyao Zhao
Luyao Zhao
YLYandi Liu
Yandi Liu
SZShiwu Zhang
Shiwu Zhang
MLMu-Ran Li
Mu-Ran Li
Background. RNF180 is a tumor suppressor gene involved in cell development, proliferation, and apoptosis. Methylation of RNF180 (mRNF180) leads to low expression of RNF180, which is closely related to the occurrence and development of gastric cancer (GC). This study was designed to evaluate the potential performance of plasma mRNF180 as noninvasive biomarker for the diagnosis of GC. Methods. A total of 156 participants, including 60 patients with GC, 39 with chronic superficial gastritis (CSG), 27 with chronic atrophic gastritis (CAG), and 30 with gastric ulcer (GU) were recruited for this study. Plasma mRNF180 level was measured using real‐time polymerase chain reaction. Results. As a diagnostic target, mRNF180 had a sensitivity of 71.67% (95% CI: 58.36%–82.18%) and specificity of 59.38% (95% CI: 48.85%–69.14%). The area under the ROC curve value of mRNF180 was 0.731 (95% CI: 0.648%–0.813%) for differentiation of GC from benign gastric diseases (BGD). The effectiveness of mRNF180 was superior to that of CEA, CA199, and CA724. mRNF180 was positively correlated with age, tumor size, T stage, N stage, M stage, and clinical stage of patients with GC. Conclusions. Plasma mRNF180 might serve as a useful and noninvasive biomarker for the diagnosis of GC and can be used to evaluate its prognosis.

2 December 2025 in Molecular Immunology
Verified
Journal Article
Closed access
MHMeijuan Han
Meijuan Han
XDXuetao Dong
Xuetao Dong
RZRuxin Zhao
Ruxin Zhao
XHXiao Hu
Xiao Hu
DLDan Li
Dan Li
MLMu-Ran Li
Mu-Ran Li

26 July 2024 in World Journal of Clinical Cases
Verified
Journal Article
Open access
JZJin-Tao Zhang
Jin-Tao Zhang
NZNan Zhang
Nan Zhang
XDXue-Tao Dong
Xue-Tao Dong
XWXiao-Ran Wang
Xiao-Ran Wang
HMHong-Wen Ma
Hong-Wen Ma
MLMu-Ran Li
Mu-Ran Li
Numerous studies have assessed the efficacy and safety of fecal microbiota tr ansplantation (FMT) as a therapy for ulcerative colitis (UC). However, the treat ment processes and outcomes of these studies vary. To evaluate the efficacy and safety of FMT for treating UC by conducting a syste matic meta-analysis. The inclusion criteria involved reports of adult patients with UC treated with FMT, while studies that did not report clinical outcomes or that included patients with infection were excluded. Clinical remission (CR) and endoscopic remission (ER) were the primary and secondary outcomes, respectively. We included nine studies retrieved from five electronic databases. The FMT group had better CR than the control group [relative risk (RR) = 1.53; 95% confidence interval (CI): 1.19-1.94; P < 0.0008]. ER was statistically significantly different between the two groups (RR = 2.80; 95%CI: 1.93-4.05; P < 0.00001). Adverse events did not differ significantly between the two groups. FMT demonstrates favorable performance and safety; however, well-designed randomized clinical trials are still needed before the widespread use of FMT can be recommended. Furthermore, standardizing the FMT process is urgently needed for improved safety and efficacy.

9 June 2026 in Materials Today Bio
Verified
Journal Article
Open access
MLMeng Li
Meng Li
XYXiaomeng Yue
Xiaomeng Yue
QLQiangwei Liu
Qiangwei Liu
JCJifang Cui
Jifang Cui
YLYandi Liu
Yandi Liu
SSShao-Kai Sun
Shao-Kai Sun
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) primarily driven by oxidative stress, sustained inflammation, barrier dysfunction, and gut dysbiosis. Current therapeutic drugs face limitations including complex synthetic processes, significant side effects, and suboptimal efficacy. Herein, we propose a simple, safe, and high-efficiency therapeutic strategy using curcumin-loaded tetrahedral framework nucleic acids (tFNAs-Cur) to reshape intestinal homeostasis in UC by coordinating barrier repair, microbiota reconstruction, and antigen presentation modulation. The synthesized tFNAs-Cur demonstrated high Cur loading, stability, water solubility, and biocompatibility. At the cellular level, tFNAs-Cur is efficiently taken up by lipopolysaccharide-stimulated RAW264.7 cells, exerting potent antioxidant and anti-inflammatory effects. In the dextran-sulfate-sodium-induced UC mouse model, tFNAs-Cur shows enhanced colon accumulation, attenuates weight loss and disease activity index, preserves colon length, repairs intact crypt architecture, and thereby restores intestinal barrier function. Further transcriptomic and biochemical analyses reveal that tFNAs-Cur alleviates IBD by upregulating H2-DMb1, potentially enhancing antigen presentation, while concurrently suppressing pro-inflammatory factors (TNF-α, IL-6, NO) and promoting anti-inflammatory cytokine IL-10. Additionally, 16S rRNA sequencing shows that tFNAs-Cur restores a healthy gut microbiota by enriching probiotic Muribaculaceae and suppressing pro-inflammatory bacteria. Collectively, tFNAs-Cur presents a safe, readily translatable, and efficient clinical candidate for UC by coordinating multiple synergistic mechanisms.